New Delhi – In a groundbreaking development for those struggling with presbyopia, Entod Pharmaceuticals has announced that its innovative eye drop, PresVu, has been approved by the Drugs Controller General of India (DCGI). This approval, granted by the Subject Expert Committee of the Central Drugs Standard Control Organization (CDSCO), marks a significant advancement in eye care.

What is Presbyopia?

Presbyopia is a common age-related vision condition that typically affects individuals over 40. It impairs the ability to focus on close objects, making tasks such as reading or threading a needle challenging. Globally, between 1.09 billion and 1.80 billion people are estimated to be affected by presbyopia, underscoring its widespread impact. The condition occurs as the eye’s natural lens becomes less flexible over time, leading to difficulties in focusing on nearby items. It is usually detected through a simple eye examination.

About PresVu

PresVu is India’s first eye drop specifically designed to address presbyopia. Developed after extensive research and development, PresVu offers a promising alternative to traditional reading glasses, contact lenses, and surgical interventions.

Key Benefits of PresVu

• Rapid Effect: PresVu improves near vision within just 15 minutes of application, providing immediate relief from the need for reading glasses.
• Lubrication: The eye drop also helps lubricate the eyes, enhancing comfort and protecting them from dryness.
• Advanced Technology: The formulation utilizes dynamic buffer technology, allowing it to quickly adapt to the pH of tears and provide extended-lasting effects.

Nikhil K. Masurkar, CEO of Entod Pharmaceuticals, expressed enthusiasm about PresVu’s potential. “The DCGI approval is a major milestone for us. PresVu represents years of dedicated research and development aimed at transforming eye care in India,” he stated. Masurkar emphasized that PresVu is more than just a product; it’s a solution designed to significantly improve the quality of life for millions.

Clinical Insights

Dr. Aditya Sethi highlighted that traditional treatments for presbyopia include reading glasses, contact lenses, and surgical options. PresVu offers a non-invasive alternative that can effectively enhance near vision, thereby simplifying daily tasks and improving overall quality of life. Dr. Dhananjay Bakhle praised the approval of PresVu as a promising advancement in ophthalmology. He noted that this eye drop provides a valuable non-invasive option for presbyopia patients, potentially reducing their reliance on reading glasses.

---

With its innovative approach and significant benefits, PresVu stands to revolutionize the way presbyopia is managed, offering a convenient and effective solution for millions of people who struggle with near vision loss. The eye drop’s approval marks a significant step forward in ophthalmic care, promising to enhance the everyday lives of those affected by presbyopia.